CytoDyn Files New Protocol with U.S. FDA for 4 Doses of Leronlimab for Critically Ill COVID-19 Patients with the Objective to Duplicate or Surpass 82% Survival Benefit with P-Value of 0.0233 Originally Achieved from Two Weeks of Treatment in CD12 Trial With 2 Doses
01 avr. 2021 06h00 HE
|
CytoDyn Inc.
Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries VANCOUVER, Washington, April 01, 2021 (GLOBE...
CytoDyn’s Leronlimab Decreased Mortality at 14 Days by 82% With Statistically Significant P-Value of 0.0233 Amongst Critically Ill COVID-19 Patients
30 mars 2021 06h00 HE
|
CytoDyn Inc.
Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value of 0.021 VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) --...
Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 days on ECMO; Case Study Published in Journal of Translational Autoimmunity
29 mars 2021 06h15 HE
|
CytoDyn Inc.
CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the...
The Philippines FDA Approves the Use of Leronlimab to Treat a COVID-19 Patient
29 mars 2021 06h00 HE
|
CytoDyn Inc.
CytoDyn is simultaneously pursuing EUA in the Philippines while expanding its access under CSP VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or...
CytoDyn to Hold Webcast on March 22 to Provide an Update on COVID-19 Initiatives and Expected Regulatory Filings with the U.S., U.K., Canada, Philippines and Brazil
18 mars 2021 00h39 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Appoints Christopher Recknor, M.D., as Chief Operating Officer
16 mars 2021 06h00 HE
|
CytoDyn Inc.
Dr. Recknor will continue to oversee the Company's COVID-19 long-haulers and Phase 2 NASH trials VANCOUVER, Washington, March 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or...
CytoDyn’s Long-Haulers COVID-19 Trial Enrolled 20 Patients Within 10 Days; Enrollment to be Completed This Month
11 mars 2021 03h34 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 11, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn to Release CD12 Trial Detailed Results via Form 8-K After Investment Community Webcast, Monday, March 8
08 mars 2021 06h10 HE
|
CytoDyn Inc.
These trial results are currently being prepared to be submitted for publication VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"),...
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
08 mars 2021 06h05 HE
|
CytoDyn Inc.
U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA CytoDyn submitted protocol to U.S. FDA for immediate enrollment of 140 critical COVID-19...
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
08 mars 2021 06h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 08, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...